Dr. Judah Folkman discovered that tumors attract blood vessels to nourish themselves through a process called angiogenesis. He found that tumors have limited growth without this blood vessel network. Later, Dr. Don Ingber also found that endothelial cells stop growing in the presence of a fungus, supporting the idea that angiogenesis can be inhibited. Today, anti-angiogenic drugs that target vascular endothelial growth factor (VEGF) are commonly used to treat stage 4 cancers by starving the tumors of nutrients. Integrating anti-angiogenic therapies with chemotherapy and radiation has shown promising results for advanced cancer patients.

1. Stage 4 Cancer Strategies That Truly Make a
Difference
Research on angiogenesis for stage 4 cancer – the method by which tumors attract
blood vessels to nourish themselves was begun by Dr. Judah Folkman, who determined
that a tumor placed in a lab container had a limited potential for growth. Moreover, he
established that the micro vascular network for the cancer could be disrupted.
Like so many great scientific minds with a new idea, Folkman was often ignored by his
colleagues and peers. While it should be said that many agreed there was evidence of
newly formed vessels – the dissenting assumption was that the detected inferior cell
networks were merely a byproduct of dying tumor cells. Some years later Folkman
could prove that they, in fact, were actually being created by the cancer cells as a
means to deliver them there much-needed nutrients.
Now consider this for a moment. The United States Government website
HealthReport.gov contends that, “Nearly one out of two Americans born today will be
diagnosed with cancer at some point in their lifetime. About 1,596,670 new cancer,
cases are expected to be diagnosed in 2011 – and about 571,950 Americans are
expected to die of cancer, more than 1,500 people a day – and cancer is the second
most common cause of death in the US, exceeded only by heart disease. In the US,
cancer alone accounts for nearly 1 of every 4 deaths." Stage 4 cancer patients are
also growing in number due to late diagnosis and often non effect treatment methods.

2. With such a destructive epidemic facing us, one would think that new ideas and
innovation would be welcomed with open arms. Nevertheless, we regularly and have
even come to expect the all-to-familiar pattern of contempt for ground-breaking
innovators and thinkers.
In another example, devoted researcher Dr. Don Ingber was studying endothelial cells
when one of his test samples became contaminated with a fungus. He was amazed to
see that in the presence of this fungus, the cells actually stopped growing. As fate
would have it, Ingber’s original position that angiogenesis could be inhibited was
ultimately supported. Today anti-angiogenic drugs are a multibillion-dollar
pharmaceutical industry and doctors like Folkan and Ingber, should receive far greater
commendation for their works – rather than the usual condemnation. Many o of these
anti-angiogenic chemotherapeutic drugs are used to manage stage 4 cancer patients.
Anti-angiogenic drugs such as sorafenib (Nexavar®), sunitinib (Sutent®), pazopanib
(Votrient®), and everolimus (Afinitor®) are typically prescribed in late-stage cancers in
order to slow growth. However, a simple agent like oxygen (non patentable) is an often
overlooked for the dominant anti-angiogenic agent that it is. In fact, oxygen metabolism
errors are involved in the cause and development of many cancers. These strategies
culminate with more than a decade of combining conventional and advanced natural
approaches to treat cancer. Understanding the role of oxygen and using is correctly is
vital for success, particularly when treating stage 4 cancer.
In light of such grim aforementioned statistics, it is imperative that we must work
collectively and with open minds to defeat the venerable adversary called cancer and
provided better methods for tackling stage 4 cancer.
Through all of the struggles some bright lights have emerged – and perhaps this one
has its place among the brightest - anti-antiogenic therapy. In simple terms, it is
designed to starve stage 4 cancer from much needed nutrients thereby blocking its
development, growth, and spread.
This is revolutionary when one considers that 90 percent of cancer patients succumb to
their disease because their cancer has spread beyond its original site (metasized) – the
picture of stage 4 cancer diagnosis. The fact that we may now inhibit tumor
angiogenesis – is a quantum leap for treatment protocols.
While such treatments are viewed as being in their fledgling states by conventional
institutions, Envita has already realized stunning success with them. In fact, it has been
found that integrating these anti-angiogenic methods with traditional chemotherapy and
radiation can work synergistically with the body and produce impressive results. These
methods seem to be very helpful for advanced stage 4 cancer patients as well.

3. Because of the incredible threat it imposes, there is no question that angiogenesis
should be blocked to stop tumor growth. In fact, without it, tumor growth is limited to a
miniscule 2 mm in size. Envita’s specifically designed cancer therapies work by shutting
off nutrients to the tumors and ultimately destroy the cancer cells that rely on them.
In addition to this approach a protein known as VEGF (*vascular endothelial growth
factor) has been identified as the agent that stimulates angiogenesis. It has been found
that a tumor releases VEGF for a variety of factors - one of which is triggered by a lack
of oxygen, or hypoxia. This process is brought into being by the transcriptional factor
HIF-1 (hypoxia inducible factor 1).
One thing we can count on is that a tumor will always attempt to grow, even beyond the
support of its existing blood supplies. As a result there is always a need for hypoxic
tissue on the tumor so it can create more VEGF. That alone is enough to suggest to
Envita that correcting a tumor’s oxygen metabolism will likely yield positive results.
You see, without VEGF tumors simply cannot grow or spread. By introducing reactive
oxygen species, it is possible to potentiate other cancer treatments as they stimulate a
change from anaerobic to aerobic that a tumor, by nature, will detest. Creating an
environment that naturally repels stage 4 cancer is a critical method by which to
facilitate and maintain remission.
But how can this be done effectively?
Well, VEGF has been shown to bind to certain cells, called endothelials, of the nearby
blood vessels. These cells diverge and grow in the direction of the tumor forming new,
albeit inferior blood vessels that actually rely on VEGF to survive. As fate would have it,
they are not as difficult as one might think to detect. So, the goal then becomes
targeting and destroying these rogue vessels while bolstering healthy ones. The end
result accelerates energy, cardiovascular stamina, and the patient’s overall endurance.
It has been determined that VEGF is connected to a broad series of tumor types,
including breast, ovarian, cervical, esophageal, lung, and cervical cancer, as well as
glioblastoma multiforme and renal cell carcinoma. It would seem that VEGF emissions
may also hinder the immune system’s ability to react and fight off the tumor - regularly
occurring in stage 4 cancers.
Remember, the immune system is our first and last defense against stage 4 cancers.
While many patients believe that their cancer has been destroyed they often find out
that dormant metastasis was biding its time to strike. We can however attempt to thwart
its efforts by correcting the body’s oxygen metabolism – thereby stopping angiogenesis
in its tracks.

4. If you know anyone who has been diagnosed with cancer or has stage 4 cancer,
please forward this article to them. We at Envita welcome you to contact us with
questions and invite you to watch our informative videos. You can also visit our PPMR
section to learn more about the power of our personalized medicine for cancer and
chronic diseases. It is important information that may save lives. Education is the best
prescription.
Take advantage of Envita’s Comprehensive Smart Oncology (link to Envita.com cancer
section) which incorporates the foremost treatment approaches and synchronizes them
with aggressive natural therapies to help each patient far greater results. Visit Envita’s
stage 4 cancer (link to Envita cancer section) therapies and strategies.
References:
*Judah Folkman <http://www.pbs.org/wgbh/nova/body/cancer-warrior.html > , <
http://en.wikipedia.org/wiki/Judah_Folkman > *Stage 4 Cancer <
http://en.wikipedia.org/wiki/Stage-4_cancer#Systems_of_staging > * Vascular
endothelial growth factor
<http://en.wikipedia.org/wiki/Vascular_endothelial_growth_factor>*HealthReform.gov
<http://www.healthreform.gov/reports/fightingcancer/index.html>*American Cancer
Society
<http://www.cancer.org/acs/groups/content/@epidemiologysurveilance/documents/docu
ment/acspc-029771.pdf>